OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of “Hold” by Brokerages

OPKO Health, Inc. (NASDAQ:OPK) has earned an average rating of “Hold” from the six analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $1.55.

A number of analysts have weighed in on OPK shares. Barrington Research cut their price objective on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th.

OPKO Health Trading Up 0.9%

NASDAQ:OPK opened at $1.18 on Friday. The stock has a 50-day simple moving average of $1.18 and a 200-day simple moving average of $1.30. The stock has a market cap of $895.70 million, a P/E ratio of -3.93 and a beta of 1.49. OPKO Health has a 1 year low of $1.10 and a 1 year high of $1.60. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.52 and a current ratio of 3.97.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. The business had revenue of $148.50 million for the quarter, compared to analyst estimates of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The business’s quarterly revenue was down 19.1% on a year-over-year basis. During the same quarter last year, the company earned $0.01 EPS. As a group, analysts anticipate that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently made changes to their positions in OPK. Caprock Group LLC acquired a new stake in shares of OPKO Health in the 3rd quarter valued at about $26,000. Zacks Investment Management acquired a new position in OPKO Health during the fourth quarter worth approximately $27,000. StoneX Group Inc. acquired a new position in OPKO Health during the fourth quarter worth approximately $27,000. Swiss Life Asset Management Ltd purchased a new stake in OPKO Health in the third quarter valued at approximately $30,000. Finally, Savant Capital LLC purchased a new stake in OPKO Health in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.